Intellia Therapeutics(NTLA)
Focus: Intellia Therapeutics is a public biotechnology company pioneering in vivo CRISPR gene editing for treating serious genetic and acquired diseases. The company operates as a clinical-stage biotech with multiple programs advancing through Phase 1-3 trials.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
16-1 this month
Stable — net -1 jobs in 30d
5 added, 6 removed. Backfill posture.
Should You Work at Intellia Therapeutics?
AI assessmentIntellia offers compelling upside for scientists/biotech professionals betting on CRISPR's clinical viability, but requires comfort with high burn rates and pre-commercial uncertainty.
Why Work Here
- Work on transformative CRISPR gene-editing platform with potential to cure monogenic diseases; recent Phase 3 data for NTLA-2002 in hereditary angioedema generated positive market momentum (June 2026).
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$36M
Pipeline & Clinical Trials
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyClinical Trials (1)
NCT05697861Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
N/AHelp build intelligence for Intellia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.